In a recent phase 2 study, the addition of the anti-FGFR2 antibody to first-line chemotherapy demonstrated superior survival in FGFR2-overexpressed GC patient cohort (the FIGHT trial) when compared to chemotherapy alone [26]. The gene discussed is FGFR2; the disease is gastric cancer.